Consortium set to list Zealand Pharma
A consortium, consisting of Life Sciences Partners and Sunstone Capital among others, has announced its intention to list Zealand Pharma A/S on the NASDAQ OMX Copenhagen.
The indicative price range per share has been set at DKK 86-120, with the final offer price expected to be published on 19 November at the latest.
Zealand Pharma is a biopharmaceutical company specialising in peptide-based drugs for the treatment of metabolic diseases such as diabetes and obesity.
The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.
If you have any information regarding this transaction, please contact Viktor Lundvall on +44 20 7004 7476 or viktor.lundvall@incisivemedia.com
More on Nordics
VC Spotlight: Climentum Capital fund to announce 10th investment this month; aims for final close at EUR 75m end-Sept
The GP expects to launch its second fund in 2025 with a target size of EUR 100m-EUR 125m
Mimir Group ramps up global origination effort with London office and focus on life science carve-outs
Stockholm-based investor is considering divestments, although challenging market remains a barrier
3i to invest in Danish children's brand Konges Sløjd
Deal aims to support the baby and children apparel group expand in Asia and the US
HG-backed Visma to divest IT consulting unit to CVC
Sponsor will invest in the carve-out from the Norwegian business software and IT provider via Fund VIII
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds